Addiction Medicine
Cost and noncompliance contribute to U.S. physicians' low use of naltrexone
Published in Medical Letter on the CDC and FDA, November 16th, 2003
According to recent research from the United States, "Naltrexone was approved by the U.S. Food and Drug Administration (FDA) in December 1994. Although it is one of only two medications for alcohol rehabilitation approved in the U.S., naltrexone is not frequently prescribed. This paper examines the factors limiting physicians' use of naltrexone."
"Data were collected through a survey of U.S. physician members of two addiction medicine professional associations," stated Tami L. Mark and collaborators at the Medstat Group and the University of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Smallpox
Orthopoxviruses detected using microarrays of immobilized oligonucleotides - Vaccine Development
Simultaneous measurement of pneumococcal polysaccharide antibodies reported - Antimicrobials
Antibiotic management program causes pseudo-outbreak of nosocomial infections - Drug Resistance
Multidrug-resistant Neisseria gonorrhoeae reported in Hawaii - Tobacco Use
Five tobacco-specific nitrosamines in cigarette smoke quantified - Air Filtration
Hong Kong hospitals get new tool for the fight against SARS - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
